Konecranes Q3 net profit rises 15% to EUR 119 million
Bitget2026/10/23 08:31- Konecranes' third-quarter comparable EBITA rose to EUR 172.2 million, while its margin fell to 15.6%.
- Net sales climbed 11% to EUR 1.1 billion, while order intake dropped 12% to EUR 1.01 billion.
- A share buyback program was launched alongside an updated strategy targeting faster profitable growth.
- For 2026, management reiterated guidance for approximately stable or higher net sales and an approximately stable comparable EBITA margin versus 2025.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
CleanSpark presents fully funded Sandersville project in investor presentation
Forge Nano completes acquisition of HzO
Crypto prices
More
